Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

Bota, Mădălina; Fischer‐Fodor, Eva; Bochiș, Ovidiu‑Vasile; Cenariu, Mihai; Popa, G; Blag, Cristina; Tătaru, Alexandru

doi:10.3892/etm.2018.6925

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To investigate the role of SPDEF and SOX4, and their downstream genes, we performed experiments in HUVECs. HUVECS have been commonly used in vitro in experiments to investigate IHs and other vascular tumors or angiogenesis in tumors [31,32]. The current studies report that the androgen-responsive gene SPDEF is mainly related to tumors -SPDEF was reported as a suppressor in tumor metastasis and progression, while some studies report otherwise [33].…”

Section: Discussionmentioning

confidence: 94%

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Chen

et al. 2020

Epigenomics

View full text Add to dashboard Cite

Aim: This study was conducted to reveal epigenetic landscape in infantile hemangiomas (IHs) and identify transcription factors (TFs) and their downstream genes active in IHs. Materials & methods: We performed Assay for Transposase Accessible Chromatin (ATAC-seq) with RNA-seq in three pairs of IHs and their adjacent normal tissues. Functions of candidate TFs were investigated in human umbilical vein endothelial cells (HUVECs). Results: Chromatin of IH tissues is less compact. Some candidate genes and TFs were identified. In HUVECs, SPDEF inhibited cell viability and tube formation, and promoted apoptosis; SOX4 exerted the opposite effect. SPDEF may act through EPHA5, ZBTB46 and SASH1; SOX4 may act through MMP12 and HIVEP3. Conclusion: Epigenetics plays a role in IHs. SPDEF and SOX4 may act in IHs.

show abstract

Section: Discussionmentioning

confidence: 94%

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Chen

et al. 2020

Epigenomics

View full text Add to dashboard Cite

show abstract

“…Bevacizumab and propranolol have already been used as solutions in the same dosage as the ones employed in the current study [ 15 , 30 ]. Regarding a possible negative interaction between drugs, there is a previous report of synergistic effects of propranolol and bevacizumab, in vitro, to inhibit the growth of human umbilical vein endothelial cells (HUVECs) and BJ human normal fibroblasts (BJs) [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial

et al. 2023

View full text Add to dashboard Cite

Background Given the persistently large public health impact of neovascular age-related macular degeneration (nARMD) despite many years of anti-VEGF therapy as the first-line treatment and the demonstrated ability of b-blockers to reduce neovascularization, a synergistic effect between an anti-VEGF agent and an intravitreal beta-blocker is important to investigate in the quest for therapeutic alternatives that maximize efficacy and/or reduce costs. The main purpose of this study is to investigate the safety of a 0.1 ml intravitreal injection of a combination of bevacizumab (1.25 mg/0.05 ml) and propranolol (50 g/0.05 ml) to treat nARMD. Methods Prospective phase I clinical trial that included patients with nARMD. Comprehensive ophthalmic evaluation was performed at baseline and included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), biomicroscopy of the anterior and posterior segments, binocular indirect ophthalmoscopy, color fundus photography, spectral domain optical coherence tomography (OCT), OCT angiography (OCT-A), fluorescein angiography (Spectralis, Heidelberg), and full-field electroretinography (ERG). All eyes were treated with a 0.1 ml intravitreal injection of a combination of bevacizumab (1.25 mg/0.05 ml) and propranolol (50 g/0.05 ml) within 1 week of baseline evaluation. The patients were reexamined at weeks 4, 8 and 12, and clinical evaluation and SD-OCT were performed at all follow-up visits. Additional injections of combination bevacizumab (1.25 mg/0.05 ml) and propranolol (50 g/0.05 ml) were administered at weeks 4 and 8. At the final study evaluation (week 12), color fundus photography, OCT-A, fluorescein angiography, and full-field ERG were repeated. Results Eleven patients (11 eyes) completed all study visits of the 12 week study. Full field ERG b-waves did not show significant (p < 0.05) changes at week 12 compared to baseline. During the 12 week follow-up period, none of the study eyes developed intraocular inflammation, endophthalmitis or intraocular pressure elevation more than 4 mmHg over baseline. Mean ± SE BCVA (logMAR) was 0.79 ± 0.09 at baseline and was significantly (p < 0.05) improved to 0.61 ± 0.10 at week 4; 0.53 ± 0.10 at week 8; and 0.51 ± 0.09 at week 12. Mean ± SE central subfield thickness (CST) (μm) was 462 ± 45 at baseline and was significantly (p < 0.05) lower at 4, 8 and 12 weeks (385 ± 37; 356 ± 29 and 341 ± 24, respectively). Conclusions In this 12 week trial of a combination of intravitreal bevacizumab and propranolol for treatment of nARMD, no adverse events or signals of ocular toxicity were observed. Further studies using this combination therapy are warranted. Trial Registration Project registered in Plataforma Brasil with CAAE number 28108920.0.0000.5440 and approved in ethics committee of Clinics Hospital of Ribeirao Preto Medicine School of São Paulo University—Ribeirão Preto, São Paulo, Brazil (appreciation number 3.999.989 gave the approval).

show abstract

“…O BVZ e o propranolol já foram utilizados separadamente em forma de soluções na mesma dosagem empregada neste estudo 34,72 . Em relação a possível interação negativa entre drogas, há um relato prévio de efeitos sinérgicos de propranolol e BVZ, in vitro, para inibir o crescimento de células endoteliais da veia umbilical humana (HUVECs) e fibroblastos humanos normais (BJs) 73 .…”

Section: Discussionunclassified

Propranolol intravítreo associado a bevacizumabe para tratamento da degeneração macular relacionada à idade exsudativa (BEVALOL study): ensaio clínico fase I

Tavares Neto

View full text Add to dashboard Cite

Ao Deus todo poderoso e à virgem Maria, por me darem oportunidades na vida e ao mesmo tempo, a força de agarrá-las e fazer o melhor que puder. Ao meu avô Edísio Tavares, que foi um grande homem, médico, cientista e sábio, por me ensinar o valor do caráter, da palavra e do estudo. À minha Avó Adoralice Celestino Ximenes, pelo seu amor infinito e doação a mim e meus irmãos. Ao meu pai Régis Borges Tavares, homem simples e amante da natureza, pelo seu amor, trabalho e dedicação à família, que me permitiu trilhar meus estudos da melhor forma. À minha mãe Conceição Tavares, mulher forte e destemida, pelo seu apoio e torcida desde que era um pequeno estudante sedento pelo saber. À minha esposa Raiza Tavares, minha fortaleza e calmaria, pelo total apoio durante o tempo que estive em Ribeirao Preto, pelo cuidado diário, pelo amor que me traz paz para trilhar meus caminhos profissionais e por carregar em seu ventre nosso maior presente, Celina. Aos meus queridos irmãos André e Marina, que torcem pela minha felicidade e compartilham esta caminhada da vida comigo. AgradecimentosAo Prof. Dr. Rodrigo Jorge, meu orientador, por me aceitar como seu pupilo na arte de fazer pesquisa e escrever artigos científicos. Por me dar oportunidades de crescimento e ensinamentos. Por se fazer sempre disponível para sanar dúvidas acerca da pesquisa e estar presente durante a construção da Tese.

show abstract

Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells

Cited by 5 publications

References 32 publications

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Characterization of Epigenetic and Transcriptional Landscape in Infantile Hemangiomas with ATAC-Seq and RNA-Seq

Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial

Propranolol intravítreo associado a bevacizumabe para tratamento da degeneração macular relacionada à idade exsudativa (BEVALOL study): ensaio clínico fase I

Contact Info

Product

Resources

About